Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for TBI-Related Attention Deficits
NCT01000064Phase 3Terminated
- Sponsor
- Vanderbilt University
- Start
- Oct 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Vanderbilt University. Started Oct 2009; status: terminated.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01000064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000064.